Capillary electrophoresis-mass spectrometry in metabolomics: The potential for driving drug discovery and development

Xu Wang; Kefeng Li; Erwin Adams; Ann Van Schepdael

doi:10.2174/13892002113149990101

Capillary electrophoresis-mass spectrometry in metabolomics: The potential for driving drug discovery and development

Xu Wang, Kefeng Li, Erwin Adams, Ann Van Schepdael

Research output: Contribution to journal › Article › peer-review

18 Citations (Scopus)

Abstract

Metabolomics represents the global profiling of metabolites in a given biological system. It has been used to facilitate pharmaceutical discovery and development for over a decade. Advances in instrumentation have positioned capillary electrophoresis-mass spectrometry (CE-MS) as an important platform for both targeted and non-targeted metabolomics. In this mini-review covering the last five years, we focus on the latest development of CE-MS based metabolomics in (a) identification and validation of novel valuable therapeutic targets, (b) evaluation of drug efficacy, and (c) monitoring of drug unanticipated adverse effects. Some of the current issues and future directions of CE-MS metabolomics are also discussed in the end.

Original language	English
Pages (from-to)	807-813
Number of pages	7
Journal	Current Drug Metabolism
Volume	14
Issue number	7
DOIs	https://doi.org/10.2174/13892002113149990101
Publication status	Published - Sept 2013
Externally published	Yes

Keywords

Biomarkers
CE-MS
Drug discovery and development
Drug efficacy
Drug toxicity metabolomics

Access to Document

10.2174/13892002113149990101

Cite this

@article{e9c0d9c562f7419fb923cfef81fa95a4,

title = "Capillary electrophoresis-mass spectrometry in metabolomics: The potential for driving drug discovery and development",

abstract = "Metabolomics represents the global profiling of metabolites in a given biological system. It has been used to facilitate pharmaceutical discovery and development for over a decade. Advances in instrumentation have positioned capillary electrophoresis-mass spectrometry (CE-MS) as an important platform for both targeted and non-targeted metabolomics. In this mini-review covering the last five years, we focus on the latest development of CE-MS based metabolomics in (a) identification and validation of novel valuable therapeutic targets, (b) evaluation of drug efficacy, and (c) monitoring of drug unanticipated adverse effects. Some of the current issues and future directions of CE-MS metabolomics are also discussed in the end.",

keywords = "Biomarkers, CE-MS, Drug discovery and development, Drug efficacy, Drug toxicity metabolomics",

author = "Xu Wang and Kefeng Li and Erwin Adams and {Van Schepdael}, Ann",

year = "2013",

month = sep,

doi = "10.2174/13892002113149990101",

language = "English",

volume = "14",

pages = "807--813",

journal = "Current Drug Metabolism",

issn = "1389-2002",

publisher = "Bentham Science Publishers B.V.",

number = "7",

}

TY - JOUR

T1 - Capillary electrophoresis-mass spectrometry in metabolomics

T2 - The potential for driving drug discovery and development

AU - Wang, Xu

AU - Li, Kefeng

AU - Adams, Erwin

AU - Van Schepdael, Ann

PY - 2013/9

Y1 - 2013/9

N2 - Metabolomics represents the global profiling of metabolites in a given biological system. It has been used to facilitate pharmaceutical discovery and development for over a decade. Advances in instrumentation have positioned capillary electrophoresis-mass spectrometry (CE-MS) as an important platform for both targeted and non-targeted metabolomics. In this mini-review covering the last five years, we focus on the latest development of CE-MS based metabolomics in (a) identification and validation of novel valuable therapeutic targets, (b) evaluation of drug efficacy, and (c) monitoring of drug unanticipated adverse effects. Some of the current issues and future directions of CE-MS metabolomics are also discussed in the end.

AB - Metabolomics represents the global profiling of metabolites in a given biological system. It has been used to facilitate pharmaceutical discovery and development for over a decade. Advances in instrumentation have positioned capillary electrophoresis-mass spectrometry (CE-MS) as an important platform for both targeted and non-targeted metabolomics. In this mini-review covering the last five years, we focus on the latest development of CE-MS based metabolomics in (a) identification and validation of novel valuable therapeutic targets, (b) evaluation of drug efficacy, and (c) monitoring of drug unanticipated adverse effects. Some of the current issues and future directions of CE-MS metabolomics are also discussed in the end.

KW - Biomarkers

KW - CE-MS

KW - Drug discovery and development

KW - Drug efficacy

KW - Drug toxicity metabolomics

UR - http://www.scopus.com/inward/record.url?scp=84887876275&partnerID=8YFLogxK

U2 - 10.2174/13892002113149990101

DO - 10.2174/13892002113149990101

M3 - Article

C2 - 23937174

AN - SCOPUS:84887876275

SN - 1389-2002

VL - 14

SP - 807

EP - 813

JO - Current Drug Metabolism

JF - Current Drug Metabolism

IS - 7

ER -

Capillary electrophoresis-mass spectrometry in metabolomics: The potential for driving drug discovery and development

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this